全文获取类型
收费全文 | 168170篇 |
免费 | 53953篇 |
国内免费 | 6006篇 |
专业分类
耳鼻咽喉 | 2177篇 |
儿科学 | 5758篇 |
妇产科学 | 1544篇 |
基础医学 | 23969篇 |
口腔科学 | 6938篇 |
临床医学 | 23954篇 |
内科学 | 34357篇 |
皮肤病学 | 8450篇 |
神经病学 | 17182篇 |
特种医学 | 5922篇 |
外国民族医学 | 30篇 |
外科学 | 22749篇 |
综合类 | 20303篇 |
现状与发展 | 22篇 |
一般理论 | 29篇 |
预防医学 | 12580篇 |
眼科学 | 3840篇 |
药学 | 16291篇 |
85篇 | |
中国医学 | 8644篇 |
肿瘤学 | 13305篇 |
出版年
2024年 | 436篇 |
2023年 | 1711篇 |
2022年 | 4166篇 |
2021年 | 6547篇 |
2020年 | 9081篇 |
2019年 | 13599篇 |
2018年 | 13145篇 |
2017年 | 14587篇 |
2016年 | 14763篇 |
2015年 | 16087篇 |
2014年 | 17040篇 |
2013年 | 17896篇 |
2012年 | 12328篇 |
2011年 | 12463篇 |
2010年 | 15178篇 |
2009年 | 10623篇 |
2008年 | 8078篇 |
2007年 | 6626篇 |
2006年 | 6262篇 |
2005年 | 5101篇 |
2004年 | 4181篇 |
2003年 | 3895篇 |
2002年 | 3353篇 |
2001年 | 2847篇 |
2000年 | 2268篇 |
1999年 | 1409篇 |
1998年 | 608篇 |
1997年 | 637篇 |
1996年 | 469篇 |
1995年 | 406篇 |
1994年 | 356篇 |
1993年 | 231篇 |
1992年 | 269篇 |
1991年 | 212篇 |
1990年 | 186篇 |
1989年 | 154篇 |
1988年 | 141篇 |
1987年 | 109篇 |
1986年 | 104篇 |
1985年 | 85篇 |
1984年 | 73篇 |
1983年 | 66篇 |
1982年 | 41篇 |
1981年 | 39篇 |
1980年 | 24篇 |
1979年 | 32篇 |
1978年 | 25篇 |
1977年 | 28篇 |
1975年 | 24篇 |
1974年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 374 毫秒
1.
目的 对比研究朝鲜淫羊藿酸性多糖酯化还原前后的理化特性,并探讨其改善油酸诱导的肝癌HepG2细胞脂质堆积活性的差异。方法 采用高效凝胶渗透色谱法测定朝鲜淫羊藿酸性多糖(EFPA)的均一性和分子量,高效液相色谱法测定EFPA和酯化还原后朝鲜淫羊藿酸性多糖(EFPA-R)的单糖组成;采用油酸(OA)处理HepG2细胞诱导建立脂质蓄积模型,不同浓度EFPA与EFPA-R(10、30、100、300 μg·mL-1)分别和OA共同作用于细胞24 h,采用CCK-8试剂盒测定细胞存活率,油红O染色观察细胞内脂滴蓄积情况,并采用试剂盒测定细胞内总胆固醇(TC)、甘油三酯(TG)含量。结果 EFPA为成分均一的多糖组分,分子量为125.8 kDa,由甘露糖、葡萄糖、半乳糖、葡萄糖醛酸和阿拉伯糖组成,摩尔比为1.7∶7.4∶1.4∶1.8∶1.0,葡萄糖占比最大,EFPA-R由甘露糖、葡萄糖、半乳糖和阿拉伯糖组成,摩尔比为0.8∶10.6∶2.1∶1.0;在10-300 μg·mL-1范围内,EFPA和EFPA-R对HepG2细胞的抑制作用较弱,作为给药浓度;与空白组相比,模型组细胞中TC、TG含量显著升高(P < 0.01),细胞内红色脂滴显著增多,与模型组相比,EFPA可显著降低细胞中TC、TG含量(P < 0.01),明显减少细胞内红色脂滴(P < 0.05或P < 0.01),EFPA-R干预后细胞则无明显变化。结论 EFPA可明显改善HepG2细胞脂质堆积情况,且呈现剂量依赖性,而半乳糖醛酸(GalA)的存在可能是其抑制HepG2细胞脂质蓄积的关键因素。 相似文献
2.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
3.
4.
5.
三阴性乳腺癌(triple negative breast cancer,TNBC)是雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)及人类表皮生长因子受体(human epidermal growth factor-2,HER-2)均不表达的乳腺癌。按其功能特征可归纳为5类分子分型:以DNA修复缺陷或生长因子为途径的基底细胞样三阴性乳腺癌;以上皮-间充质转化和肿瘤干细胞为特征的间质样三阴性乳腺癌;免疫调节型三阴性乳腺癌;雄激素受体过表达的管腔/分泌型三阴性乳腺癌;HER-2富集型三阴性乳腺癌。三阴性乳腺癌恶性程度高且异型性较大,其治疗困难且预后较差,内分泌治疗及靶向治疗不敏感。目前很多学者对于三阴性乳腺癌的治疗各有研究,并有临床试验证实下述治疗有效。 相似文献
6.
Sung‐Hyun Hwang Myung‐Chul Kim Sumin Ji Yeseul Yang Yeji Jeong Yongbaek Kim 《Cancer science》2019,110(4):1256-1267
Metformin, a drug for type 2 diabetes mellitus, has shown therapeutic effects for various cancers. However, it had no beneficial effects on the survival rate of human malignant mesothelioma (HMM) patients. The present study was performed to elucidate the underlying mechanism of metformin resistance in HMM cells. Glucose‐starved HMM cells had enhanced resistance to metformin, demonstrated by decreased apoptosis and autophagy and increased cell survival. These cells showed abnormalities in mitochondria, such as decreased ATP synthesis, morphological elongation, altered mitochondrial permeability transition pore and hyperpolarization of mitochondrial membrane potential (MMP). Intriguingly, Mdr1 was significantly upregulated in mitochondria but not in cell membrane. The upregulated mitochondrial Mdr1 was reversed by treatment with carbonyl cyanide m‐chlorophenyl hydrazone, an MMP depolarization inducer. Furthermore, apoptosis and autophagy were increased in multidrug resistance protein 1 knockout HMM cells cultured under glucose starvation with metformin treatment. The data suggest that mitochondrial Mdr1 plays a critical role in the chemoresistance to metformin in HMM cells, which could be a potential target for improving its therapeutic efficacy. 相似文献
7.
8.
Xiying Fan Glen A. Bjerke Kent Riemondy Li Wang Rui Yi 《Molecular carcinogenesis》2019,58(12):2241-2253
MicroRNAs (miRNAs) play important roles in prostate cancer development. However, it remains unclear how individual miRNAs contribute to the initiation and progression of prostate cancer. Here we show that a basal layer‐enriched miRNA is required for prostate tumorigenesis. We identify miR‐205 as the most highly expressed miRNA and enriched in the basal cells of the prostate. Although miR‐205 is not required for normal prostate development and homeostasis, genetic deletion of miR‐205 in a Pten null tumor model significantly compromises tumor progression and does not promote metastasis. In Pten null basal cells, loss of miR‐205 attenuates pAkt levels and promotes cellular senescence. Furthermore, although overexpression of miR‐205 in prostate cancer cells with luminal phenotypes inhibits cell growth in both human and mouse, miR‐205 has a minimal effect on the growth of a normal human prostate cell line. Taken together, we have provided genetic evidence for a requirement of miR‐205 in the progression of Pten null‐induced prostate cancer. 相似文献
9.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
10.